BioWorld

Jan. 28, 2009

View Archived Issues

CVT Rejects $1B Acquisition Offer from Partner Astellas

Astellas Pharma Inc. revealed Tuesday that it has spent the last year attempting to acquire CV Therapeutics Inc., but the biotech rejected its latest $1 billion offer and declined to engage in further discussions. (BioWorld Today) Read More

Theravance Files Telavancin NDA for Hospital-Acquired Pneumonia

Read More

Obama Election Called End of 'Sad Chapter' for Science

Read More

Mixed Bag of Pipeline News for Amgen as Earnings Fall Short

Read More

Drugmakers Slow to Personalized Medicine Risk Market Share

Read More

UK Report on Start-ups Calls for New Source of Funding

Read More

NitroMed Agrees to Deerfield Sale, but also Vows to Shop Around

Read More

Other News To Note

Read More

Clinic Roundup

Read More